Galderma Publishes the P-III (OLYMPIA 1) Trial of Nemolizumab for Prurigo Nodularis in JAMA Dermatology
Shots:
- The P-III (OLYMPIA 1) study assessed nemolizumab vs PBO in patients (n=286; at least 18yrs.) with mod. to sev. prurigo nodularis for 24wks.
- Study showed 4-pt. improved itch intensity in 58.4% vs 16.7% & skin lesion clearance in 26.3% vs 7.3% at wk.16., while itch response in 41.1% vs 6.3%, PP-NRS score <2 in 21.6% vs 1% (improving to 34.2% vs 4.2% by wk.16) & 4-pt. improved sleep disturbance in 31.1% vs 5.2% (improving to 50% vs 11.5% by wk.16) by wk.4
- Nemolizumab is approved in the US for prurigo nodularis. Other applications for prurigo nodularis & atopic dermatitis are under review in the EU, Australia, Singapore, Switzerland, Canada, Brazil & South Korea, with additional submissions ongoing
Ref: Galderma | Image: Galderma
Related News:- Unlocking Approval: Baldo Scassellati Sforzolini from Galderma in a Stimulating Dialogue Exchange with PharmaShots
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
